Skip to content
10-Q

Quarterly Report

ADC Therapeutics SA ADCT

0001628280-26-029819

← back to feed
Filed
May 4, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 27, 2026 127.19M sh
Shares Diluted Q1 2026 · Mar 31, 2026 154.14M sh
Shares Diluted Q1 2026 · Mar 31, 2025 107.2M sh
Capex Q1 2026 · Mar 31, 2026 $32K
Capex Q1 2026 · Mar 31, 2025 $264K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$29.71M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$56.33M
Short Term Debt Q1 2026 · Mar 31, 2026 $4.64M
Short Term Debt Q1 2026 · Dec 31, 2025 $3M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $231.01M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $261.34M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$216.38M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$185.83M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$238.22M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$202.64M
Current Liabilities Q1 2026 · Mar 31, 2026 $67.63M
Current Liabilities Q1 2026 · Dec 31, 2025 $70.16M
Total Liabilities Q1 2026 · Mar 31, 2026 $507.87M
Total Liabilities Q1 2026 · Dec 31, 2025 $508.98M
Current Assets Q1 2026 · Mar 31, 2026 $276.77M
Current Assets Q1 2026 · Dec 31, 2025 $306.34M
Total Assets Q1 2026 · Mar 31, 2026 $291.5M
Total Assets Q1 2026 · Dec 31, 2025 $323.15M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.21
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.36
Eps Basic Q1 2026 · Mar 31, 2026 −$0.21
Eps Basic Q1 2026 · Mar 31, 2025 −$0.36
Sga Expense Q1 2026 · Mar 31, 2026 $9.9M
Sga Expense Q1 2026 · Mar 31, 2025 $9.96M
Rd Expense Q1 2026 · Mar 31, 2026 $19.88M
Rd Expense Q1 2026 · Mar 31, 2025 $28.93M
Net Income Q1 2026 · Mar 31, 2026 −$32.97M
Net Income Q1 2026 · Mar 31, 2025 −$38.6M
Operating Income Q1 2026 · Mar 31, 2026 −$25.25M
Operating Income Q1 2026 · Mar 31, 2025 −$28.46M
Revenue Q1 2026 · Mar 31, 2026 $20.03M
Revenue Q1 2026 · Mar 31, 2025 $17.4M